Worldwide prevalence of haemorrhoids: a systematic review and meta-analysis.

Ann MedDec 26, 2025 (epub)
Clinical ResearchGastroenterologyOpen access

Amin Esmaeilnia Shirvani, Kimia Pakdaman, Zahra Maleki et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis assessed haemorrhoidal disease prevalence across general, clinical, and high-risk populations. It included 150 studies (210 datasets) comprising 8,960,338 individuals. The pooled global point prevalence was 25.92% (95% CI: 22.62-29.22); lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Estimates varied by population and diagnostic method, with higher prevalence reported in women and with invasive diagnostic methods.

Key findings

  • Pooled global point prevalence was 25.92% (95% CI: 22.62-29.22).
  • Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97).
  • Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men.
  • Invasive diagnostic methods yielded higher prevalence estimates (28.05%, 95% CI: 23.86-32.26) than non-invasive methods.

Why it matters

The pooled estimates indicate that haemorrhoidal disease is common across the populations represented in the evidence base. Differences by sex and diagnostic approach show that prevalence figures depend partly on who is assessed and how disease is identified. Awareness of these factors can help clinicians interpret reported burden and recognise that estimates from different settings may not be directly comparable.

What to keep in mind

The review combined studies from general, clinical, and high-risk populations using different diagnostic methods, which may contribute to variation in prevalence estimates.

Source

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.